Emergent BioSolutions | EBS - Assets


Emergent BioSolutions reported $1.82B in Assets for its fiscal quarter ending in December of 2023.





Assets Change Date
Acadia Pharmaceuticals USD 1.56B 233.42M Dec/2025
Akebia Therapeutics USD 376.56M 12.41M Dec/2025
ALKERMES USD 2.49B 157.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amarin USD 670.78M 10.96M Dec/2025
ANI Pharmaceuticals USD 1.44B 32.22M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Coherus Biosciences USD 258.34M 258.18M Dec/2025
Emergent BioSolutions USD 1.82B 69.9M Dec/2023
Exelixis USD 2.84B 20.87M Dec/2025
Glaxosmithkline GBP 82.34B 102.25M Dec/2025
Heron Therapeutics USD 255.88M 6.93M Dec/2025
Ionis Pharmaceuticals USD 3.52B 490.91M Dec/2025
Ironwood Pharmaceuticals USD 396.06M 53.12M Sep/2025
Lexicon Pharmaceuticals USD 184.99M 20.94M Dec/2025
Lonza CHF 18.97B 164M Dec/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Myriad Genetics USD 706.6M 21.5M Dec/2025
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.63B 365.8M Dec/2025
Pacira USD 1.26B 32.66M Dec/2025
Pfizer USD 208.73B 2.64B Sep/2025
PTC Therapeutics USD 2.9B 255.07M Dec/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.35B 143.73M Dec/2025
United Therapeutics USD 7.88B 528.9M Dec/2025
Vanda Pharmaceuticals USD 488.95M 112.19M Dec/2025
Xoma USD 263.15M 39.7M Sep/2025